UPCC 17419: A Phase 1b-2 Open-Label Study of JNJ-68284528 a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

Brief description of study

The main purpose of this study is to investigate the use of a new, experimental drug called JNJ-68284528 in subjects with multiple myeloma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Myeloma
  • Age: - 99 Years
  • Gender: All
Updated on 29 Jan 2020. Study ID: 833182

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center